Dialysis industry news

Stories from the dialysis comunity across the globe.



Lipocalin-2 may be a biomarker for renal disease activity in patients with ... - Healio PDF Print

Urinary lipocalin-2 levels may be a useful biomarker for detecting renal disease activity in patients with lupus nephritis, according to the results of a study.

Researchers studied 50 adult patients with systemic lupus erythematosus (SLE) who met 1997 American College of Rheumatology (ACR) criteria and 20 matched healthy participants.

All participants underwent clinical and serological evaluation. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were calculated for patients with SLE. Urinary lipocalin-2 was measured in all participants.

Patients with SLE had significantly higher levels of urinary lipocalin-2 compared to healthy participants (13.2 /mL vs. 1.7 /mL), and patients with lupus nephritis had significantly higher levels of lipocalin-2 than all participants (22.95 /mL). Renal SLEDAI scores correlated positively with increased levels of lipocalin-2, but the levels did not correlate with other symptoms of disease unrelated to renal involvement.

Of 25 patients with 1-year follow-up data available, a significant difference was seen in urinary lipocalin-2 levels between patients with and without lupus nephritis. An association between the change in the total and renal SLEDAI scores and urinary lipocalin-2 levels was noted but it did not reach statistical significance.

The authors concluded that the levels of urinary lipocalin-2 may be useful in predicting renal disease activity in patients with SLE. – by Shirley Pulawski

Reference:

Gamal NM, et al. Paper #SAT0413. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology. June 10-13, 2015; Rome.

Disclosure: The researchers report no relevant financial disclosures.

...

 
Company Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) Drops by -9.45% - Insider Trading Report PDF Print

Rockwell Medical, Inc. (NASDAQ:RMTI) has lost 9.45% during the past week and dropped 29.76% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 10.05%. Rockwell Medical, Inc. (NASDAQ:RMTI) has underperformed the index by 28.58% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

The company shares have rallied 12.7% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $15.63 and the 200 day moving average is recorded at $12.13. S&P 500 has rallied 6.56% during the last 52-weeks. The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Rockwell Medical, Inc. is up 26.12% in the last 3-month period. Year-to-Date the stock performance stands at 23.05%. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Friday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $11.53 and hit $12.79 on the upside , eventually ending the session at $12.65, with a gain of 9.62% or 1.11 points. The heightened volatility saw the trading volume jump to 1,234,072 shares. The 52-week high of the share price is $18.8999 and the company has a market cap of $635 million. The 52-week low of the share price is at $8.095 . Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0.73% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

 
Government acquires 21 dialysis machines - Zambia Daily Mail PDF Print
dialysis2

NANCY MWAPE, Livingstone
GOVERNMENT has acquired 21 dialysis machines from Germany for three referral hospitals at a cost of €1 million.
The dialysis machines are for Lusaka’s University Teaching Hospital (UTH), Livingstone Central and Ndola Central hospitals.
Deputy Health minister Chitalu Chilufya said in an interview on Saturday that Government will ensure that all hospitals have dialysis machines to enable them handle kidney complications without referring them abroad.
“This is a significant step in our health delivery. Our plan is to ensure that each provincial hospital is equipped with dialysis machines to arrest increasing cases of kidney-related complications.
“Government’s plan is to finish installing dialysis machines in all hospitals by the year 2017,” Dr Chilufya said.
A dialysis machine is used to filter a patient’s blood to remove excess water and waste products when kidneys are damaged.
Dr Chilufya said installation of dialysis machines at Livingstone Central Hospital will elevate the status of the institution and help improve service delivery.
Livingstone Central Hospital consultant physician and nephrologist Kenneth Kapembwa said in a separate interview that the acquisition of the dialysis machines will help prevent deaths among patients with chronic kidney disease.
“The machine will not just focus on kidney patients but also other people requiring dialysis for other medical procedures to be done,” he said.
Dr Kapembwa said the setting up of a dialysis unit at the Livingstone Central will enable the hospital to provide tertiary level services, which have been lacking for a long time.
He said the hospital is currently losing many patients suffering from kidney failure due to lack of dialysis machines.
Dr Kapembwa said medical staff will be trained before the hospital starts offering the service.

...

 
Badulla General Hospital gets a new dialysis unit - The Official Government News Portal of Sri Lanka PDF Print

The unit which was established in 2012 with one bed now has more facilities and four beds. Patients seeking the service of Kandy, Mahiyanganaya and Monaragala hospitals can obtain the service from Badulla hospital without having to travel long distances, they said.

 

Arrangements have been made to establish a kidney transplant unit and an eight storeyed building at Badulla General Hospital premises. The new unit and the building to be built will offer advanced services for kidney patients and to reduce congestion, the Health Ministry sources added.

...

 
Company Shares of DaVita healthCare Partners Inc. (NYSE:DVA) Drops by -0.91% - News Watch International PDF Print

DaVita healthCare Partners Inc. (NYSE:DVA) has dropped 0.91% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 0.39% in the last 4 weeks. The shares have underperformed the S&P 500 by 1.58% during the past week but DaVita healthCare Partners Inc. (NYSE:DVA) has outperformed the index in 4 weeks by 2.07%.

The company shares have rallied 10.46% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $85.17 and one year low was seen on August 15, 2014 at $71.43. The 50-day moving average is $79.76 and the 200 day moving average is recorded at $80. S&P 500 has rallied 6.56% during the last 52-weeks. The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares have been rated as hold from 7 Wall Street Analysts. 1 analysts have suggested buy for the company. Underperform rating was given by 1 analyst. DaVita HealthCare Partners Inc. has dropped 1.47% during the last 3-month period . Year-to-Date the stock performance stands at 5.99%. DaVita healthCare Partners Inc. (NYSE:DVA) : On Friday heightened volatility was witnessed in DaVita healthCare Partners Inc. (NYSE:DVA) which led to swings in the share price. The shares opened for trading at $79.71 and hit $80.315 on the upside , eventually ending the session at $80.28, with a gain of 0.79% or 0.63 points. The heightened volatility saw the trading volume jump to 533,027 shares. The 52-week high of the share price is $85.17 and the company has a market cap of $17,300 million. The 52-week low of the share price is at $71.43 . Currently the company Insiders own 0.2% of DaVita HealthCare Partners Inc. Company shares. In the past six months, there is a change of -52.05% in the total insider ownership. Institutional Investors own 86.2% of Company shares. During last 3 month period, -0.15% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Jiganti Jeanine Marie, officer (Chief Compliance Officer) of Davita Healthcare Partners Inc., had unloaded 1,311 shares at an average price of $81.37 in a transaction dated on August 10, 2015. The total value of the transaction was worth $106,676. DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysias Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd. NO COMMENTS LEAVE A REPLY Cancel reply

...

 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 16 of 4210
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.